Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 5:48 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | Venrock Healthcare Capital Partners III L.P. | 4,026,331 8.500% | 1,071,429 (+36.26%) | View |
| 2024-11-14 5:46 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | RA CAPITAL MANAGEMENT L.P. | 1,061,233 2.200% | 1,061,233 (New Position) | View |
| 2024-11-14 4:24 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | CITADEL ADVISORS LLC | 1,734,094 3.700% | 1,307,237 (+306.25%) | View |
| 2024-11-14 4:15 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | Fairmount Funds Management LLC | 3,202,798 6.800% | 1,071,429 (+50.27%) | View |
| 2024-11-14 4:05 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | COMMODORE CAPITAL LP | 4,100,000 8.700% | 1,198,184 (+41.29%) | View |
| 2024-11-13 5:55 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | Polar Capital Holdings Plc | 2,687,797 5.690% | 2,687,797 (New Position) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Enliven Therapeutics Inc. ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 0 (Unchanged) | View |
| 2024-10-24 2:02 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 2,936,642 (New Position) | View |
| 2024-07-29 6:12 pm Sale | 13D | Enliven Therapeutics Inc. ELVN | 5AM Ventures VI L.P. | 2,304,332 4.900% | -531,543 (-18.74%) | View |
| 2024-05-20 4:55 pm Sale | 13D | Enliven Therapeutics Inc. ELVN | ORBIMED ADVISORS LLC | 7,918,163 16.800% | -1,033,300 (-11.54%) | View |
| 2024-04-15 7:21 pm Sale | 13D | Enliven Therapeutics Inc. ELVN | 5AM Ventures VI L.P. | 2,835,875 6.100% | -1,000,100 (-26.07%) | View |
| 2024-04-04 4:39 pm Purchase | 13D | Enliven Therapeutics Inc. ELVN | ORBIMED ADVISORS LLC | 8,951,463 19.200% | 2,124 (+0.02%) | View |
| 2024-02-16 4:15 pm Sale | 13D | Enliven Therapeutics Inc. ELVN | 5AM Ventures VI L.P. | 3,835,975 9.300% | -825,000 (-17.70%) | View |
| 2024-02-14 8:53 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.200% | 740,760 (+33.46%) | View |
| 2024-02-14 4:58 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | CITADEL ADVISORS LLC | 2,394,448 5.800% | 95,692 (+4.16%) | View |
| 2024-02-14 4:05 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | COMMODORE CAPITAL LP | 2,901,816 7.000% | 819,693 (+39.37%) | View |
| 2024-02-14 3:45 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | Fairmount Funds Management LLC | 2,131,369 5.200% | 6,744 (+0.32%) | View |
| 2024-02-14 3:31 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | PFIZER INC PFE | 389,429 0.950% | 389,429 (New Position) | View |
| 2024-02-09 09:03 am Purchase | 13G | Enliven Therapeutics Inc. ELVN | FMR LLC | 5,902,265 14.321% | 1,482,684 (+33.55%) | View |
| 2024-02-07 12:16 pm Purchase | 13G | Enliven Therapeutics Inc. ELVN | BML Investment Partners L.P. | 50,000 0.100% | 50,000 (New Position) | View |